Ahead Therapeutics has reached an agreement with Prof. Dr. med.-univ. Schett from University Erlangen-Nürnberg to advance in the preclinical development of AT_1001.

The agreement will allow Ahead Therapeutics to validate the platform potential of the PS-Liposomes using the Rheumatoid Arthritis in vivo model developed by the group of Prof. Dr. Med. Georg Schett. All the experiments will be performed at the Erlangen University by researchers from the professor’s group.